Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study

NCT02227784 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02227784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2014
Completion date
December 31, 2015
Enrollment
366 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia